MDGL - CONSENSUS CO - Madrigal Pharmaceuticals

This daily price chart for Madrigal Pharmaceuticals (MDGL) illustrates the price action of an asset with a consensus of 679.24. The business leverages its status as the world's first developer of NASH therapy, ensuring high profitability and strong free cash flow. Management has shifted its focus from science toward sales and engagement with insurers, as patient access to MASH medication determines the viability of the entire model.

This indicator represents the weighted average of target prices from leading analysts, reflecting a real-time fundamental revaluation of the business. By analyzing the consensus valuation chart with a current value of 679.24, an investor can compare market hype with the potential for market monopolization in MASH treatment provided by the unique drug from Madrigal Pharmaceuticals (MDGL).